Loading…
BioLife Solutions, Inc. is projected to rise to $29.12 by 2027, a +19% move from its current price of $24.50. BLFS is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $23.87 | $24.51 | $25.15 | +0.03% |
| May 30 | $23.62 | $24.51 | $25.43 | +0.05% |
| May 31 | $23.43 | $24.52 | $25.65 | +0.08% |
| Jun 1 | $23.28 | $24.53 | $25.84 | +0.10% |
| Jun 2 | $23.14 | $24.53 | $26.01 | +0.13% |
| Jun 3 | $23.02 | $24.54 | $26.16 | +0.16% |
| Jun 4 | $22.91 | $24.54 | $26.30 | +0.18% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $22.91 | $24.54 | $26.30 | +0.18% |
| Week 2 | $22.30 | $24.59 | $27.11 | +0.36% |
| Week 3 | $21.86 | $24.63 | $27.76 | +0.55% |
| Week 4 | $21.49 | $24.68 | $28.34 | +0.73% |
| Week 5 | $21.18 | $24.72 | $28.85 | +0.91% |
| Week 6 | $20.91 | $24.77 | $29.33 | +1.09% |
| Week 7 | $20.67 | $24.81 | $29.79 | +1.28% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction products, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; CryoCase cryo-compatible transparent rigid containers for closed-system fill and retrieval, and automated cell processing machines; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors.
The company was incorporated in 1987 and is headquartered in Bothell, Washington.
BioLife Solutions, Inc. (BLFS) trades in the Healthcare sector. It is currently priced at $23.95 per share and has a market capitalization of $1.17B, with a market rank of 2411. The current price sits near a bullish technical backdrop, and the forecast data provide a multi-year upside potential from 2026 through 2050.
A major floor 25.9% below — a decisive break under it would weaken the trend.
The nearest floor, 18.4% below — buyers have tended to step in here.
Price is pressing into resistance (1.0% away) — a breakout level to watch.
A major ceiling 13.6% above — clearing it would confirm fresh momentum.
Key BLFS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BLFS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $24.24 | Buy | $23.98 | Buy |
| MA 10 | $22.96 | Buy | $23.35 | Buy |
| MA 20 | $22.22 | Buy | $22.59 | Buy |
| MA 50 | $21.00 | Buy | $21.82 | Buy |
| MA 100 | $21.87 | Buy | $22.11 | Buy |
| MA 200 | $23.85 | Buy | $22.83 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 65.16 | Neutral |
| Stoch RSI (14) | 82.99 | Sell |
| CCI (20) | 127.34 | Buy |
| Williams %R (14) | -6.03 | Info |
| MACD (12,26,9) | 0.26 | Buy |
| ROC (12) | 11.16 | Buy |
| Bollinger %B (20,2) | 0.92 | Neutral |
| Stochastic %K (14) | 93.97 | Sell |
| TRIX (15) | 0.40 | Buy |
| Awesome (5,34) | 2.44 | Buy |
| Ultimate (7,14,28) | 76.07 | Sell |
| Momentum (10) | 3.27 | Buy |
| Aroon Osc (25) | 64.00 | Buy |
| Hull MA (9) | 24.84 | Sell |
| ADX (14) | 17.51 | Neutral |
| ATR (14) | 0.57 | Info |
The near-term technical picture is bullish. The RSI(14) is 60, with the 50-day simple moving average at $20.78 and the 200-day simple moving average at $23.83. Support is identified at $19.99 and resistance at $24.74, framing a 30-day price range of $19.98 to $28.70.
The stock exhibits an annualized volatility of 50%, indicating substantial price movement within the month.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $18.15 | $24.50 | $32.60 | 0% | Neutral | |
| $23.19 | $29.12 | $38.67 | +19% | Neutral | |
| $23.69 | $30.52 | $41.96 | +25% | Bullish | |
| $29.93 | $39.41 | $55.66 | +61% | Bullish | |
| $35.61 | $47.78 | $69.06 | +95% | Bullish | |
| $36.22 | $49.46 | $72.94 | +102% | Bullish | |
| $38.89 | $53.97 | $81.06 | +120% | Bullish | |
| $40.62 | $57.25 | $87.40 | +134% | Bullish | |
| $41.95 | $59.99 | $92.99 | +145% | Bullish | |
| $44.93 | $65.15 | $102.43 | +166% | Bullish | |
| $66.25 | $102.31 | $170.70 | +318% | Bullish | |
| $119.25 | $205.16 | $373.39 | +737% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $18.15 | $24.50 | $28.85 | +0.00% |
| June 2026 | $21.53 | $25.27 | $30.33 | +3.12% |
| July 2026 | $21.21 | $25.09 | $30.50 | -0.71% |
| August 2026 | $20.92 | $24.90 | $30.58 | -0.73% |
| September 2026 | $21.54 | $25.77 | $31.91 | +3.49% |
| October 2026 | $21.92 | $26.35 | $32.86 | +2.24% |
| November 2026 | $21.42 | $25.86 | $32.46 | -1.85% |
| December 2026 | $21.30 | $25.81 | $32.60 | -0.19% |
Click any year to see its month-by-month BLFS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
BioLife Solutions, Inc.'s 2026 outlook centres on $24.50, within a $18.15 to $32.60 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, BLFS could reach as high as $38.67, with a base case around $29.12 and support toward $23.19 — roughly +19% from $24.50. A consolidation phase looks the most probable path here.
Expect BLFS to range from $23.69 to $41.96 through 2028. The $30.52 average target implies a +25% move from current prices. That is up +5% on the projected 2027 average. Momentum favours further upside here.
The BLFS price prediction for 2029 points to an average of $39.41 (low $29.93, high $55.66) — a potential gain of +61% on today's $24.50. Buyers look set to stay in control over this stretch.
In 2030, BLFS is projected to trade between $35.61 and $69.06, averaging $47.78 — a potential gain of +95% from today's $24.50. That is up +21% on the projected 2029 average. Momentum favours further upside here.
BioLife Solutions, Inc.'s 2031 outlook centres on $49.46, within a $36.22 to $72.94 range. That is up +4% on the projected 2030 average. That marks a +102% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, BLFS could reach as high as $81.06, with a base case around $53.97 and support toward $38.89 — roughly +120% from $24.50. Momentum favours further upside here.
Expect BLFS to range from $40.62 to $87.40 through 2033. The $57.25 average target implies a +134% move from current prices. That is up +6% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The BLFS price prediction for 2034 points to an average of $59.99 (low $41.95, high $92.99) — a potential gain of +145% on today's $24.50. Momentum favours further upside here.
In 2035, BLFS is projected to trade between $44.93 and $102.43, averaging $65.15 — a potential gain of +166% from today's $24.50. That is up +9% on the projected 2034 average. Buyers look set to stay in control over this stretch.
BioLife Solutions, Inc.'s 2040 outlook centres on $102.31, within a $66.25 to $170.70 range. That is up +57% on the projected 2035 average. That marks a +318% change versus current levels. Momentum favours further upside here.
By 2050, BLFS could reach as high as $373.39, with a base case around $205.16 and support toward $119.25 — roughly +737% from $24.50. Buyers look set to stay in control over this stretch.
Investing $1,000 in BLFS today (≈ 40.816327 BLFS) could be worth
$8,373.97
+$7,373.97 (+737%) by 2050 · US Dollar
Based on the average projected BLFS price of $205.16 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BLFSwould be worth at today's price.
$1,000 invested in BLFS on May 27, 2025 (≈ 44.923629 BLFS) would be worth
$1,100.63
+$100.63 (+10.1%) today · 1.10× · US Dollar
Based on a BLFS entry price of $22.26 vs. today's $24.5.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $24 | $1,020.83 | +2.1% |
| 1 month ago | $21.41 | $1,144.33 | +14.4% |
| 3 months ago | $22.48 | $1,089.86 | +9.0% |
| 6 months ago | $26.5 | $924.53 | -7.5% |
| 1 year ago | $22.26 | $1,100.63 | +10.1% |
| All time (5.0y) ago | $32.27 | $759.22 | -24.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BLFS forecast.
Our base-case forecast reaches $49.00 around 2031.
Implied market cap at $49.00: $2.39B
The multi-year forecast shows a strong upside trajectory. The 2026 average is $23.95 with a 0 ROI, followed by a steady climb to 2027 average $28.39 (18.5 ROI), 2028 average $29.53 (23.3), 2029 average $38.77 (61.9), 2030 average $46.92 (95.9), 2031 average $47.98 (100.3), 2032 average $52.93 (121), 2033 average $55.86 (133.2), 2034 average $57.81 (141.4), and 2035 average $63.51 (165.2). The forecast extends to 2040 with an average of $99.00 (313.4) and to 2050 with an average of $200.05 (735.3), with bullish sentiment indicated for these years.
These figures represent estimates and are not guarantees, as outcomes depend on market conditions and company performance.
Tap a question to reveal the answer.
The forecast shows an average price of $46.92 in 2030 with an ROI of 95.9, and a max forecast of $68.53.
The long-run forecast shows bullish sentiment with averages rising to $46.92 by 2030 and $200.05 by 2050, corresponding to ROIs of 95.9 and 735.3, respectively, but these are estimates and involve risk.
The 2040 forecast shows an average of $99.00, with a max forecast of $167.81 and an ROI of 313.4.
The current price is $23.95 per share and the market capitalization is $1.17B.
The 30-day range spans from $19.98 to $28.70.
BioLife Solutions, Inc. Community Discussion
0Share your BioLife Solutions, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.